4-(6-氨基吡啶-3-基)苯甲酸 | 222986-51-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-(6-氨基吡啶-3-基)苯甲酸
• 英文名称: 4-(6-aminopyridin-3-yl)benzoic acid
• 英文别名: 4-(2-aminopyridin-5-yl)benzoic acid
• CAS: 222986-51-8
• 化学式: C₁₂H₁₀N₂O₂
• mdl: MFCD06801984
• 分子量: 214.224
• InChiKey: DAAPYOWCDXFHOC-UHFFFAOYSA-N

物化性质

• 沸点：
  438.7±35.0 °C(Predicted)
• 密度：
  1.316±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  76.2
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

4-(6-氨基吡啶-3-基)苯甲酸MSDS英文版

反应信息

• 作为反应物：
  描述：

  2,3-二氨基苯甲酰胺盐酸盐 、 4-(6-氨基吡啶-3-基)苯甲酸 在 N,N'-羰基二咪唑 作用下， 以 吡啶 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  Benzimidazole derivatives as potential dual inhibitors for PARP-1 and DHODH

  摘要：

  Poly (ADP-ribose) polymerases (PARPs) play diverse roles in various cellular processes that involve DNA repair and programmed cell death. Amongst these polymerases is PARP-1 which is the key DNA damage-sensing enzyme that acts as an initiator for the DNA repair mechanism. Dihydroorotate dehydrogenase (DHODH) is an enzyme in the pyrimidine biosynthetic pathway which is an important target for anti-hyperproliferative and anti-inflammatory drug design. Since these enzymes share a common role in the DNA replication and repair mechanisms, it may be beneficial to target both PARP-1 and DHODH in attempts to design new anti-cancer agents.Benzimidazole derivatives have shown a wide variety of pharmacological activities including PARP and DHODH inhibition. We hereby report the design, synthesis and bioactivities of a series of benzimidazole derivatives as inhibitors of both the PARP-1 and DHODH enzymes. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.05.051
• 作为产物：
  描述：

  2-氨基-5-溴吡啶 、 4-溴苯甲酸 在 四(三苯基膦)钯 、 caesium carbonate 作用下， 以 水 、 乙腈 为溶剂， 反应 48.0h， 以73%的产率得到4-(6-氨基吡啶-3-基)苯甲酸
  参考文献：
  名称：

  以氨基酸为柔性接头的新型 Bcr-AblT315I 抑制剂的设计、合成和生物学评价

  摘要：

  尽管伊马替尼通过 Bcr-Abl 抑制在 CML 治疗中取得了成功，但随着时间的推移，患者会出现获得性耐药性。特别是T315I突变引起的耐药性在临床上仍然是一个挑战。在此，我们开始了一项结构优化活动，旨在基于先前报道的二苯甲酰哌嗪衍生物发现针对 T315I 突变体的新型 Bcr-Abl 抑制剂。我们提出，通过避免与 Ile315 庞大侧链的空间冲突，柔性接头的掺入可以实现对 Bcr-Abl T315I的有效抑制。已经开发和评估了一个包含 28 种以氨基酸为接头的化合物的文库。其中，化合物AA2对 Bcr-Abl WT和 Bcr-Abl T315I的活性最强，以及朝向 Bcr-Abl 驱动的 K562 和 K562R 细胞。进一步的研究表明AA2可以诱导K562细胞凋亡并下调Bcr-Abl的磷酸化。综上所述，氨基酸作为新型柔性接头的化合物表现出一定的抗肿瘤活性，为发现新型 Bcr-Abl 抑制剂克服

  DOI：

  10.1016/j.bmc.2021.116398

文献信息

• NOVEL SULFONYL DERIVATIVES
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1104754A1

  公开（公告）日：2001-06-06

  Sulfonyl derivatives represented by the following general formula (I): Q1-Q2-T1-Q3-SO2-QA and drugs containing the same (wherein Q1 is an optionally substituted, saturated or unsaturated, five- or six-membered cyclic hydrocarbon group, a five- or six-membered heterocyclic group, or the like; Q2 is a single band, oxygen, sulfur, C1-C6 alkylene or the like; QA is optionally substituted arylalkenyl, heteroarylalkenyl or the like; and T1 is carbonyl or the like). These compounds have potent FXa-inhibitory effects and promptly exert satisfactory and persistent antithrombotic effects through oral administration, thus being useful as anticoagulant agents little accompanied with side effects.

  以下是通用公式（I）所代表的磺酰衍生物：Q1-Q2-T1-Q3-SO2-QA以及含有这些衍生物的药物（其中Q1是可选择地取代的饱和或不饱和的五元或六元环烃基团，五元或六元杂环基团等；Q2是单键，氧，硫，C1-C6烷基或类似物；QA是可选择地取代的芳基烯烃基团，杂环芳基烯烃基团或类似物；T1是羰基或类似物）。这些化合物具有强大的FXa抑制作用，并通过口服迅速产生令人满意且持久的抗血栓作用，因此可作为几乎不伴随副作用的抗凝血剂。
• Novel sulfonyl derivatives
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：US20040082611A1

  公开（公告）日：2004-04-29

  Described in the present invention are a sulfonyl derivative represented by the following formula (I): Q 1 -Q 2 -T 1 -Q 3 -SO 2 -Q A (I) [wherein Q 1 represents a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group, 5- or 6-membered heterocyclic group, dicyclic fused ring or tricyclic fused ring group which may have a substituent; Q 2 represents a single bond, an oxygen atom, a sulfur atom, a linear or branched C 1-6 alkylene group or the like; Q A represents an arylalkenyl group which may have a substituent or a heteroarylalkenyl group which may have a substituent; and T 1 represents a carbonyl group or the like] and a medicament comprising the same. The compound has strong FXa inhibitory action, provides prompt, sufficient and long-lasting anti-thrombus effects when orally administered, and has low side effects and is therefore useful as an excellent anticoagulant.

  本发明描述了一种由以下式(I)表示的磺酰基衍生物： Q1-Q2-T1-Q3-SO2-QA(I) [其中，Q1表示饱和或不饱和的5-或6-环烃基、5-或6-杂环基、二环融合环或三环融合环基，可能具有取代基；Q2表示单键、氧原子、硫原子、线性或支链的C1-6烷基等；QA表示可能具有取代基的芳基烯基或杂芳基烯基；T1表示羰基基团或类似物]，以及包含该化合物的药物。该化合物具有强烈的FXa抑制作用，口服后提供快速、充分和持久的抗血栓效果，并且具有低副作用，因此可用作优秀的抗凝剂。
• Sulfonyl derivatives
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：US20030232808A1

  公开（公告）日：2003-12-18

  Described is a sulfonyl derivative represented by the following formula (I): 1 [wherein R 1 represents a hydrogen atom, a hydroxyl group, a nitro group or the like, R 2 and R 3 each independently represents a hydrogen atom, a halogen atom or the like, R 4 and R 5 each independently represents a hydrogen atom, a halogen atom or the like, Q 1 represents a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like, Q 2 represents a single bond, an oxygen atom or the like, Q 3 represents any one of the following groups: 2 T 1 represents a carbonyl group or the like, and X 1 and X 2 each independently represents a methine group or a nitrogen atom]; or salt thereof; or solvate thereof. The sulfonyl derivative, salt or solvate according to the present invention is novel as an excellent anticoagulant and it has strong FXa inhibitory action, rapidly exhibits sufficient and long-lasting anti-thrombus effects after oral administration and has less side effects.

  本发明涉及一种磺酰基衍生物，其表示为以下式子（I）：1[其中，R1代表氢原子、羟基、硝基或类似物，R2和R3各自独立地代表氢原子、卤素原子或类似物，R4和R5各自独立地代表氢原子、卤素原子或类似物，Q1代表饱和或不饱和的5或6元环烃基，可以被取代，或类似物，Q2代表单键、氧原子或类似物，Q3代表以下任意一种基团：2T1代表羰基或类似物，X1和X2各自独立地代表亚甲基基团或氮原子]；或其盐；或其溶剂化物。根据本发明的磺酰基衍生物，盐或溶剂化物作为一种优异的抗凝血剂是新颖的，具有强烈的FXa抑制作用，在口服后迅速表现出足够持久的抗血栓效果，并且副作用较少。
• Novel ethylenediamine derivatives
  申请人：Nakamoto Yumi

  公开号：US20070129371A1

  公开（公告）日：2007-06-07

  A compound represented by the following formula (1): Q 1 —Q 2 —T o —N(R 1 )—Q 3 —N(R 2 )—T 1 —Q 4 ( 1 ) [wherein, R 1 and R 2 are hydrogen atoms or the like; Q 1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may have a substituent, or the like; Q 2 is a single bond or the like; Q 3 represents the following group: —C(R 3a )(R 4a )—C(R 3b )(R 4b )}m 1 —C(R 3c )(R 4c )}m 2 —C(R 3d )(R 4d )}m 3 —C(R 3e )(R 4e )}m 4 —C (R 3f )(R 4f )— (in which, R 3a to R 4e represent hydrogen or the like); T 0 represents a carbonyl group or the like; and T 1 represents —COCONR— or the like]; or salt thereof, solvate thereof, or N-oxide thereof. The compound is useful as a preventive and/or therapeutic agent for cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

  以下化合物公式（1）表示的化合物：Q1-Q2-To-N（R1）-Q3-N（R2）-T1-Q4（1）[其中，R1和R2是氢原子或类似物；Q1是饱和或不饱和的5或6元环烃基，可以具有取代基或类似物；Q2是单键或类似物；Q3表示以下基团：-C（R3a）（R4a）-C（R3b）（R4b）}m1-C（R3c）（R4c）}m2-C（R3d）（R4d）}m3-C（R3e）（R4e）}m4-C（R3f）（R4f）-（其中，R3a到R4e代表氢或类似物）；T0表示羰基基团或类似物；T1表示-COCONR-或类似物]；或其盐，溶剂化合物或N-氧化物。该化合物可用作预防和/或治疗脑梗死、脑栓塞、心肌梗死、心绞痛、肺梗死、肺栓塞、布尔格病、深静脉血栓形成、弥漫性血管内凝血综合征、瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、全身性炎症反应综合征（SIRS）、多器官功能障碍综合征（MODS）、体外循环期间的血栓形成或采血时的血液凝固。
• Antibacterial agents
  申请人：Andersen Niels H.

  公开号：US20110172174A1

  公开（公告）日：2011-07-14

  Antibacterial compounds of formula I are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.

  本发明提供了化学式I的抗菌化合物，包括立体异构体、药学上可接受的盐、酯和前药；包括这些化合物的药物组合物；通过给予这些化合物的途径来治疗细菌感染的方法；以及制备这些化合物的方法。